Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus

Laura J V Piddock; Yu Fang Jin; Mark A Webber; Martin J Everett

doi:10.1128/AAC.46.7.2276-2278.2002

Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus

Antimicrob Agents Chemother. 2002 Jul;46(7):2276-8. doi: 10.1128/AAC.46.7.2276-2278.2002.

Authors

Laura J V Piddock¹, Yu Fang Jin, Mark A Webber, Martin J Everett

Affiliation

¹ Antimicrobial Agents Research Group, Division of Immunity & Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom. L.j.v.piddock@bham.ac.uk

Abstract

A ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus (F145) contained no mutations within gyrA, gyrB, grlA, and grlB or within norA or its promoter region. MICs and accumulation studies suggest the role of a novel multidrug efflux pump.

MeSH terms

Anti-Infective Agents / pharmacology*
Carbonyl Cyanide m-Chlorophenyl Hydrazone / pharmacology
Ciprofloxacin / pharmacology*
Microbial Sensitivity Tests
Mutation
Nalidixic Acid / pharmacology*
Staphylococcus aureus / drug effects*
Staphylococcus aureus / genetics

Substances

Anti-Infective Agents
Nalidixic Acid
Carbonyl Cyanide m-Chlorophenyl Hydrazone
Ciprofloxacin